Centre Hospitalier Universitaire de Reims
Reims, 51100, France
NCT Number: NCT02210481
Comparison between intravitreous glucose rate and macular thinning measured by Ocular Coherence Tomography (OCT) at 3 months post vitrectomy for retinal detachment or epimacular membrane. Hypothesis : Association between post-operative macular thickness and intravitreous glucose rate
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Reims, 51100, France
Comparison between intravitreous glucose rate and macular thinning measured by OCT at 3 months post vitrectomy for retinal detachment or epimacular membrane. The cohort is divided in 2 groups, one with the thinnest macular measurement under 190µm, and the others above 190µm. We are looking for a correlation between increasing glucose rates and decreased macular thickness.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 months post-operatively
Time frame: 3 months post-operatively
CHU de Reims
Other
Impact of Intravitreal Glucose Rate in Macular Thinning Following Retinal Detachment or Epimacular Membrane Surgery
Acronym: GLU-MAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05710458
Epiretinal Membrane, Eye Diseases
Hong Kong
View Trial DetailsNCT07495319
Eye Diseases, Retina Disorder
Karachi, Pakistan
View Trial DetailsNCT03902795
Eye Diseases, Nervous System Diseases
Lublin, Poland
View Trial DetailsNCT02222857
Acute Retinal Necrosis, Eye Diseases
Taipei, Taiwan
View Trial Details